InnoPharmax Total Liabilities

The latest total liabilities for 4172.TWO is $52M as of June 2026. That compares with $43M in the prior-year period — up 20.3% year over year. Investors often review this figure alongside InnoPharmax's historical trend and sector peers before judging valuation or financial health.

Over the past year, 4172.TWO's total liabilities moved from $43M to $52M — a 20.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in InnoPharmax's operating scale or balance-sheet position.

A total liabilities figure of $52M for 4172.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 4172.TWO's total liabilities ($52M), review year-over-year change from $43M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.